ARS Pharmaceuticals, Inc.SPRYEarnings & Financial Report
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
Revenue
$2.1M
Gross Profit
N/A
Operating Profit
$-21.7M
Net Profit
$-19.1M
Gross Margin
N/A
Operating Margin
-1051.6%
Net Margin
-925.0%
YoY Growth
N/A
EPS
$-0.20
ARS Pharmaceuticals, Inc. Q3 FY2024 Financial Summary
ARS Pharmaceuticals, Inc. reported revenue of $2.1M for Q3 FY2024, with a net profit of $-19.1M (down 28.7% YoY) (-925.0% margin).
Key Financial Metrics
| Total Revenue | $2.1M |
|---|---|
| Net Profit | $-19.1M |
| Gross Margin | N/A |
| Operating Margin | -1051.6% |
| Report Period | Q3 FY2024 |
ARS Pharmaceuticals, Inc. Annual Revenue by Year
ARS Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $84.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $84.3M |
| 2024 | $89.1M |
| 2023 | $30.0K |
| 2022 | $1.3M |
ARS Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
ARS Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $28.1M | -67.6% | $-41.3M | -147.1% |
| Q3 FY2025 | $32.5M | +1471.6% | $-51.2M | -157.4% |
| Q2 FY2025 | $15.7M | +3043.4% | $-44.9M | -285.6% |
| Q1 FY2025 | $8.0M | — | $-33.9M | -425.7% |
| Q4 FY2024 | $86.6M | — | $49.9M | 57.7% |
| Q3 FY2024 | $2.1M | — | $-19.1M | -925.0% |
| Q2 FY2024 | $500.0K | +4900.0% | $-12.5M | -2503.2% |
| Q1 FY2024 | $0 | — | $-10.3M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $500000 | $2.1M | $86.6M | $8.0M | $15.7M | $32.5M | $28.1M |
| YoY Growth | N/A | 4900.0% | N/A | N/A | N/A | 3043.4% | 1471.6% | -67.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $227.6M | $222.0M | $217.6M | $351.2M | $327.3M | $313.5M | $372.8M | $327.7M |
| Liabilities | $3.7M | $6.7M | $16.6M | $94.4M | $98.3M | $121.2M | $225.1M | $213.4M |
| Equity | $223.9M | $215.2M | $201.0M | $256.8M | $229.0M | $192.3M | $147.7M | $114.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.7M | $-7.3M | $-14.5M | $42.0M | $-40.7M | $-39.6M | $-47.0M | $-43.5M |